Literature DB >> 8212859

Protection of three strains of mice against lethal influenza in vivo by defective interfering virus.

D J Morgan1, L McLain, N J Dimmock.   

Abstract

This report examines the protective effects of defective interfering (DI) WSN on three strains of mice (C3H/He-mg (H-2k), C57BL/6 (H-2b) and BALB/c (H-2d)) infected with various doses of A/WSN influenza virus. All three strains were protected in terms of morbidity and mortality, to varying extents, DI WSN protected optimally against a low but lethal dose of A/WSN in C3H/He-mg mice, but also protected this and other strains against very high doses of A/WSN. Intermediate sized inocula gave little, if any, protection. In all cases protection required an active DI genome since inactivation with beta-propiolactone abrogated any sparing effect. Consolidation of the lungs was reduced by treatment with active DI virus, but at some doses of inoculum there was reduction in lung pathology without reduction of mortality. Treatment of infected mice with DI virus did not reduce the lung virus titre, but in C3H/He-mg mice resulted in recovery of infectious virus from other tissues, notably the heart, where it was not normally found. No infectivity was recovered from brain, liver or serum. Haemagglutination-inhibiting (HI) antibody could not be detected in the lungs of any of the infected mice co-inoculated with the control BPL-inactivated DI WSN but was present in considerable amounts in all three strains when these were co-inoculated with DI virus. These and previous data (Morgan and Dimmock, 1992) suggested that influenza virus was immunosuppressive and that active DI virus abrogated these suppressive effects.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8212859     DOI: 10.1016/0168-1702(93)90058-u

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  5 in total

Review 1.  Defective interfering influenza virus RNAs: time to reevaluate their clinical potential as broad-spectrum antivirals?

Authors:  Nigel J Dimmock; Andrew J Easton
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

2.  Defective interfering influenza virus confers only short-lived protection against influenza virus disease: evidence for a role for adaptive immunity in DI virus-mediated protection in vivo.

Authors:  Paul D Scott; Bo Meng; Anthony C Marriott; Andrew J Easton; Nigel J Dimmock
Journal:  Vaccine       Date:  2011-07-14       Impact factor: 3.641

3.  Defective viral genomes arising in vivo provide critical danger signals for the triggering of lung antiviral immunity.

Authors:  Karla Tapia; Won-Keun Kim; Yan Sun; Xiomara Mercado-López; Emily Dunay; Megan Wise; Michael Adu; Carolina B López
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

4.  Comparison of the protection of ferrets against pandemic 2009 influenza A virus (H1N1) by 244 DI influenza virus and oseltamivir.

Authors:  Nigel J Dimmock; Brian K Dove; Bo Meng; Paul D Scott; Irene Taylor; Linda Cheung; Bassam Hallis; Anthony C Marriott; Miles W Carroll; Andrew J Easton
Journal:  Antiviral Res       Date:  2012-10-04       Impact factor: 5.970

5.  Antigen-specific B-cell receptor sensitizes B cells to infection by influenza virus.

Authors:  Stephanie K Dougan; Joseph Ashour; Roos A Karssemeijer; Maximilian W Popp; Ana M Avalos; Marta Barisa; Arwen F Altenburg; Jessica R Ingram; Juan Jose Cragnolini; Chunguang Guo; Frederick W Alt; Rudolf Jaenisch; Hidde L Ploegh
Journal:  Nature       Date:  2013-10-20       Impact factor: 49.962

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.